Troxerutin protects against 2,2',4,4'-tetrabromodiphenyl ether (BDE-47)-induced liver inflammation by attenuating oxidative stress-mediated NAD+-depletion

Journal of Hazardous Materials

Volumn 283, Issue , 2015, Pages 98-109

  Zhang, Zi Feng ^a,b   Zhang, Yan Qiu ^a   Fan, Shao Hua ^b   Zhuang, Juan ^a   Zheng, Yuan Lin ^b   Lu, Jun ^b   Wu, Dong Mei ^b   Shan, Qun ^b   Hu, Bin ^b  

^a CHINA UNIVERSITY OF MINING AND TECHNOLOGY   (China)

^b JIANGSU NORMAL UNIVERSITY   (China)

Author keywords

Inflammation; NAD+; Oxidative stress; Polybrominated diphenyl ethers; Troxerutin

Indexed keywords

ACETYLATION; DISEASES; ETHERS; MAMMALS; ORGANIC POLLUTANTS; OXIDATIVE STRESS; PATHOLOGY; TOXICITY; TRANSCRIPTION;

INFLAMMATION; INFLAMMATORY RESPONSE; NAD^+; NATURAL BIOFLAVONOIDS; NUCLEAR TRANSLOCATIONS; POLYBROMINATED DIPHENYL ETHER (PBDES); PROTEIN EXPRESSIONS; TROXERUTIN;

FLAVONOIDS;

2,2',4,4' TETRABROMODIPHENYL ETHER; ALPHA TOCOPHEROL; EX 527; HISTONE H3; HYDROLASE INHIBITOR; LYSINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; ORGANOBROMINE DERIVATIVE; SIRTUIN 1; TRANSCRIPTION FACTOR RELA; TROXERUTIN; UNCLASSIFIED DRUG; 2,2',4,4'-TETRABROMODIPHENYL ETHER; ANTIOXIDANT; DANGEROUS GOODS; DIPHENYL ETHER DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOXERUTIN;

ANTIOXIDANT; DISEASE INCIDENCE; ETHER; GENE EXPRESSION; OXIDATION; RODENT; STRESS ANALYSIS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; GENE REPRESSION; HEPATITIS; INFLAMMATION; LIVER; LIVER INJURY; LIVER TOXICITY; MALE; MEDIATOR; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN ACETYLATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; DANGEROUS GOODS; DRUG EFFECTS; METABOLISM; TOXICITY;

ANIMALS; ANTIOXIDANTS; HALOGENATED DIPHENYL ETHERS; HAZARDOUS SUBSTANCES; HYDROXYETHYLRUTOSIDE; LIVER; MICE; NF-KAPPA B; OXIDATIVE STRESS;

EID: 84907513115     PISSN: 03043894     EISSN: 18733336     Source Type: Journal    
DOI: 10.1016/j.jhazmat.2014.09.012     Document Type: Article

References (60)

1. Alaee M., Arias P., Sjödin A., Bergman A. An overview of commercially used brominated flame retardants, their applications, their use patterns in different countries/regions and possible modes of release. Environ. Int. 2003, 29:683-689.
2. Hoffman K., Adgent M., Goldman B.D., Sjödin A., Daniels J.L. Lactational exposure to polybrominated diphenyl ethers and its relation to social and emotional development among toddlers. Environ. Health Perspect. 2012, 120:1438-1442.
3. Woods R., Vallero R.O., Golub M.S., Suarez J.K., Ta T.A., Yasui D.H., Chi L.H., Kostyniak P.J., Pessah I.N., Berman R.F., LaSalle J.M. Long-lived epigenetic interactions between perinatal PBDE exposure and Mecp2308 mutation. Hum. Mol. Genet. 2012, 21:2399-2411.
4. Kim U.J., Kim M.Y., Hong Y.H., Lee D.H., Oh J.E. Assessment of impact of internal exposure to PBDEs on human thyroid function--comparison between congenital hypothyroidism and normal paired blood. Environ. Sci. Technol. 2012, 46:6261-6268.
5. Dunnick J.K., Nyska A. Characterization of liver toxicity in F344/N rats and B6C3F1 mice after exposure to a flame retardant containing lower molecular weight polybrominated diphenyl ethers. Exp. Toxicol. Pathol. 2009, 61:1-12.
6. Lupton S.J., McGarrigle B.P., Olson J.R., Wood T.D., Aga D.S. Human liver microsome-mediated metabolism of brominated diphenyl ethers 47, 99, and 153 and identification of their major metabolites. Chem. Res. Toxicol. 2009, 22:1802-1809.
7. Wu N., Herrmann T., Paepke O., Tickner J., Hale R., Harvey L.E., La Guardia M., McClean M.D., Webster T.F. Human exposure to PBDEs: associations of PBDE body burdens with food consumption and house dust concentrations. Environ. Sci. Technol. 2007, 41:1584-1589.
8. Fromme H., Körner W., Shahin N., Wanner A., Albrecht M., Boehmer S., Parlar H., Mayer R., Liebl B., Bolte G. Human exposure to polybrominated diphenyl ethers (PBDE), as evidenced by data from a duplicate diet study, indoor air, house dust, and biomonitoring in Germany. Environ. Int. 2009, 35:1125-1135.
9. Bocio A., Llobet J.M., Domingo J.L., Corbella J., Teixidó A., Casas C. Polybrominated diphenyl ethers (PBDEs) in foodstuffs: human exposure through the diet. J. Agric. Food Chem. 2003, 51:3191-3195.
10. Meeker J.D., Johnson P.I., Camann D., Hauser R. Polybrominated diphenyl ether (PBDE) concentrations in house dust are related to hormone levels in men. Sci. Total Environ. 2009, 407:3425-3429.
11. Chevrier J., Harley K.G., Bradman A., Gharbi M., Sjödin A., Eskenazi B. Polybrominated diphenyl ether (PBDE) flame retardants and thyroid hormone during pregnancy. Environ. Health Perspect. 2010, 118:1444-1449.
12. Gascon M., Vrijheid M., Martínez D., Forns J., Grimalt J.O., Torrent M., Sunyer J. Effects of pre and postnatal exposure to low levels of polybromodiphenyl ethers on neurodevelopment and thyroid hormone levels at 4 years of age. Environ. Int. 2011, 37:605-611.
13. Chen A., Yolton K., Rauch S.A., Webster G.M., Hornung R., Sjödin A., Dietrich K.N., Lanphear B.P. Prenatal polybrominated diphenyl ether exposures and neurodevelopment in U.S. children through 5 years of age: the HOME study. Environ. Health Perspect. 2014, 122:856-862.
14. Richardson V.M., Staskal D.F., Ross D.G., Diliberto J.J., DeVito M.J., Birnbaum L.S. Possible mechanisms of thyroid hormone disruption in mice by BDE 47, a major polybrominated diphenyl ether congener. Toxicol. Appl. Pharmacol. 2008, 226:244-250.
15. Maranghi F., Tassinari R., Moracci G., Altieri I., Rasinger J.D., Carroll T.S., Hogstrand C., Lundebye A.K., Mantovani A. Dietary exposure of juvenile female mice to polyhalogenated seafood contaminants (HBCD, BDE-47, PCB-153, TCDD): comparative assessment of effects in potential target tissues. Food Chem. Toxicol. 2013, 56:443-449.
16. Shao J., White C.C., Dabrowski M.J., Kavanagh T.J., Eckert M.L., Gallagher E.P. The role of mitochondrial and oxidative injury in BDE 47 toxicity to human fetal liver hematopoietic stem cells. Toxicol. Sci. 2008, 101:81-90.
17. Mouchiroud L., Houtkooper R.H., Moullan N., Katsyuba E., Ryu D., Cantó C., Mottis A., Jo Y.S., Viswanathan M., Schoonjans K., Guarente L., Auwerx J. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 2013, 154:430-441.
18. Peek C.B., Affinati A.H., Ramsey K.M., Kuo H.Y., Yu W., Sena L.A., Ilkayeva O., Marcheva B., Kobayashi Y., Omura C., Levine D.C., Bacsik D.J., Gius D., Newgard C.B., Goetzman E., Chandel N.S., Denu J.M., Mrksich M., Bass J. Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science 2013, 342:1243417.
19. Escande C., Nin V., Price N.L., Capellini V., Gomes A.P., Barbosa M.T., O'Neil L., White T.A., Sinclair D.A., Chini E.N. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes 2013, 62:1084-1093.
20. Choi S.E., Fu T., Seok S., Kim D.H., Yu E., Lee K.W., Kang Y., Li X., Kemper B., Kemper J.K. Elevated microRNA-34a in obesity reduces NAD(+) levels and SIRT1 activity by directly targeting NAMPT. Aging Cell 2013, 12:1062-1072.
21. Menssen A., Hydbring P., Kapelle K., Vervoorts J., Diebold J., Lüscher B., Larsson L.G., Hermeking H. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E187-E196.
22. Schreiber V., Dantzer F., Ame J.C., de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7:517-528.
23. Módis K., Gero D., Erdélyi K., Szoleczky P., DeWitt D., Szabo C. Cellular bioenergetics is regulated by PARP1 under resting conditions and during oxidative stress. Biochem. Pharmacol. 2012, 83:633-643.
24. Kauppinen A., Suuronen T., Ojala J., Kaarniranta K., Salminen A. Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal. 2013, 25:1939-1948.
25. Hwang J.W., Yao H., Caito S., Sundar I.K., Rahman I. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic. Biol. Med. 2013, 61C:95-110.
26. Lu J., Wu D.M., Zheng Z.H., Zheng Y.L., Hu B., Zhang Z.F. Troxerutin protects against high cholesterol-induced cognitive deficits in mice. Brain 2011, 134:783-797.
27. Lu J., Wu D.M., Zheng Y.L., Hu B., Cheng W., Zhang Z.F., Li M.Q. Troxerutin counteracts domoic acid-induced memory deficits in mice by inhibiting CCAAT/enhancer binding protein β-mediated inflammatory response and oxidative stress. J. Immunol. 2013, 190:3466-3479.
28. Zhang Z.F., Fan S.H., Zheng Y.L., Lu J., Wu D.M., Shan Q., Hu B. Troxerutin protects the mouse liver against oxidative stress-mediated injury induced by D-galactose. J. Agric. Food Chem. 2009, 57:7731-7736.
29. Wang L., Zou W., Zhong Y., An J., Zhang X., Wu M., Yu Z. The hormesis effect of BDE-47 in HepG2 cells and the potential molecular mechanism. Toxicol. Lett. 2012, 209:193-201.
30. de Kreutzenberg S.V., Ceolotto G., Papparella I., Bortoluzzi A., Semplicini A., Dalla Man C., Cobelli C., Fadini G.P., Avogaro A. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 2010, 59:1006-1015.
31. Chen H., Wang Y., Zhang J., Ma Y., Wang C., Zhou Y., Gu H., Ying W. NAD(+)-carrying mesoporous silica nanoparticles can prevent oxidative stress-induced energy failures of both rodent astrocytes and PC12 cells. PLoS One 2013, 8:e74100.
32. Aggarwal B.B., Sundaram C., Prasad S., Kannappan R. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem. Pharmacol. 2010, 80:1613-1631.
33. Fan S.H., Zhang Z.F., Zheng Y.L., Lu J., Wu D.M., Shan Q., Hu B., Wang Y.Y. Troxerutin protects the mouse kidney from d-galactose-caused injury through anti-inflammation and anti-oxidation. Int. Immunopharmacol. 2009, 9:91-96.
34. Nie Y., Erion D.M., Yuan Z., Dietrich M., Shulman G.I., Horvath T.L., Gao Q. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat. Cell Biol. 2009, 11:492-500.
35. Zhang Z.F., Lu J., Zheng Y.L., Wu D.M., Hu B., Shan Q., Cheng W., Li M.Q., Sun Y.Y. Purple sweet potato color attenuates hepatic insulin resistance via blocking oxidative stress and endoplasmic reticulum stress in high-fat-diet-treated mice. J. Nutr. Biochem. 2013, 24:1008-1018.
36. Li P., Fan W., Xu J., Lu M., Yamamoto H., Auwerx J., Sears D.D., Talukdar S., Oh D., Chen A., Bandyopadhyay G., Scadeng M., Ofrecio J.M., Nalbandian S., Olefsky J.M. Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity. Cell 2011, 147:815-826.
37. Ji K., Choi K., Giesy J.P., Musarrat J., Takeda S. Genotoxicity of several polybrominated diphenyl ethers (PBDEs) and hydroxylated PBDEs, and their mechanisms of toxicity. Environ. Sci. Technol. 2011, 45:5003-5008.
38. Xing T.R., Yong W., Chen L., Tang M.L., Wang M., Chen J.T., Ruan D.Y. Effects of decabrominated diphenyl ether (PBDE 209) on voltage-gated sodium channels in primary cultured rat hippocampal neurons. Environ. Toxicol. 2010, 25:400-408.
39. Blanco J., Mulero M., Domingo J.L., Sánchez D.J. Gestational exposure to BDE-99 produces toxicity through upregulation of CYP isoforms and ROS production in the fetal rat liver. Toxicol. Sci. 2012, 127:296-302.
40. Costa L.G., de Laat R., Tagliaferri S., Pellacani C. A mechanistic view of polybrominated diphenyl ether (PBDE) developmental neurotoxicity. Toxicol. Lett. 2014, 230:282-294.
41. Park H.R., Kamau P.W., Loch-Caruso R. Involvement of reactive oxygen species in brominated diphenyl ether-47-induced inflammatory cytokine release from human extravillous trophoblasts in vitro. Toxicol. Appl. Pharmacol. 2014, 274:283-292.
42. Dalleau S., Baradat M., Guéraud F., Huc L. Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. Cell Death Differ. 2013, 20:1615-1630.
43. Miller D.M., Singh I.N., Wang J.A., Hall E.D. Administration of the Nrf2-ARE activators sulforaphane and carnosic acid attenuates 4-hydroxy-2-nonenal-induced mitochondrial dysfunction ex vivo. Free Radic. Biol. Med. 2013, 57:1-9.
44. Houtkooper R.H., Auwerx J. Exploring the therapeutic space around NAD+. J. Cell Biol. 2012, 199:205-209.
45. Belenky P., Racette F.G., Bogan K.L., McClure J.M., Smith J.S., Brenner C. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 2007, 129:473-484.
46. + metabolism: a therapeutic target for age-related metabolic disease. Crit. Rev. Biochem. Mol. Biol. 2013, 48:397-408.
47. Imai S., Yoshino J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes. Metab. 2013, 15:26-33.
48. Yoshino J., Mills K.F., Yoon M.J., Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011, 14:528-536.
49. Orlando G., Khoronenkova S.V., Dianova I.I., Parsons J.L., Dianov G.L. ARF induction in response to DNA strand breaks is regulated by PARP1. Nucleic Acids Res. 2014, 42:2320-2329.
50. Pang J., Gong H., Xi C., Fan W., Dai Y., Zhang T.M. Poly(ADP-ribose) polymerase 1 is involved in glucose toxicity through SIRT1 modulation in HepG2 hepatocytes. J. Cell Biochem. 2011, 112:299-306.
51. Li H., Xu M., Lee J., He C., Xie Z. Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E1234-E1244.
52. Wani W.Y., Sunkaria A., Sharma D.R., Kandimalla R.J., Kaushal A., Gerace E., Chiarugi A., Gill K.D. Caspase inhibition augments Dichlorvos-induced dopaminergic neuronal cell death by increasing ROS production and PARP1 activation. Neuroscience 2014, 258:1-15.
53. Cantó C., Gerhart-Hines Z., Feige J.N., Lagouge M., Noriega L., Milne J.C., Elliott P.J., Puigserver P., Auwerx J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
54. Qin W.D., Wei S.J., Wang X.P., Wang J., Wang W.K., Liu F., Gong L., Yan F., Zhang Y., Zhang M. Poly(ADP-ribose) polymerase 1 inhibition protects against low shear stress induced inflammation. Biochim. Biophys. Acta 2013, 1833:59-68.
55. Yang H., Zhang W., Pan H., Feldser H.G., Lainez E., Miller C., Leung S., Zhong Z., Zhao H., Sweitzer S., Considine T., Riera T., Suri V., White B., Ellis J.L., Vlasuk G.P., Loh C. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. PLoS One 2012, 7:e46364.
56. Gillum M.P., Kotas M.E., Erion D.M., Kursawe R., Chatterjee P., Nead K.T., Muise E.S., Hsiao J.J., Frederick D.W., Yonemitsu S., Banks A.S., Qiang L., Bhanot S., Olefsky J.M., Sears D.D., Caprio S., Shulman G.I. SirT1 regulates adipose tissue inflammation. Diabetes 2011, 60:3235-3245.
57. Balasubramanyam K., Varier R.A., Altaf M., Swaminathan V., Siddappa N.B., Ranga U., Kundu T.K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279:51163-51171.
58. Choi K.C., Jung M.G., Lee Y.H., Yoon J.C., Kwon S.H., Kang H.B., Kim M.J., Cha J.H., Kim Y.J., Jun W.J., Lee J.M., Yoon H.G. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 2009, 69:583-592.
59. Smith K. Liver disease: kupffer cells regulate the progression of ALD and NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:503.
60. Miura K., Kodama Y., Inokuchi S., Schnabl B., Aoyama T., Ohnishi H., Olefsky J.M., Brenner D.A., Seki E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139:323-334.